Study of Dapagliflozin to Protect Kidney Function in Adults on Peritoneal Dialysis

What this Trial Is About

This research aims to study the effects of dapagliflozin on preserving residual renal function RRF in patients undergoing peritoneal dialysis PD. Residual renal function helps remove water and waste from the body, supports hormone secretion, and maintains internal balance. Current methods to protect RRF in PD patients have limited impact, and while dapagliflozin, an SGLT2 inhibitor, is used for diabetes and has shown kidney protection in non-dialysis patients, its role in PD patients is not yet known. Participants are randomly assigned to one of two groups for 24 weeks one group receives dapagliflozin 10 mg orally once daily along with standard treatments such as peritoneal dialysis and medications for blood pressure and blood sugar control the other group receives only the standard treatments without dapagliflozin. This study is designed to explore dapagliflozins potential benefits on kidney function and heart health in these patients. During the study, researchers will measure changes in urine volume, kidney function, heart markers, blood sugar, sodium levels, blood pressure, body weight, and episodes of peritonitis or hospitalization at various points from baseline up to 24 weeks. They will also monitor levels of dapagliflozin and its metabolites in urine, dialysate, and blood. Participant involvement includes regular tests and assessments to track these health indicators and treatment effects throughout the study period.

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients